Magnelium (Magnesium glucoheptonate) - A Dietary Supplement

Magnesium glucoheptonate (Magnelium) is an important cofactor in various enzymatic reactions. It is used in patients with magnesium deficiency such as those with malnutrition and those with malabsorption.

Magnesium glucoheptonate Uses:

As a dietary supplement, it is utilised.

Magnesium glucoheptonate Dose in Adults:

Dose in the therapy of Hypomagnesemia:

1,500–3,000 mg or 75–150 mg of elemental magnesium taken orally once daily or three times per day are comparable to 15–30 mL.

Use in Children:

Not indicated for use in children.

Pregnancy Risk Category: D

Magnesium can cross the placental barrier. The mother and fetus have the same serum concentrations.

Magnesium glucoheptonate use during breastfeeding:

Magnesium can be excreted from breastmilk, and the serum levels of mother and infant during the first year are the same regardless of the maternal serum levels.
The maternal requirements for lactation are the exact same as those of women who aren't breastfeeding.

Dose in Kidney disease:

Mild or moderate impairment:
- Dose adjustments have not been provided by the manufacturer.
- However, accumulation of the drug may occur resulting in toxicity.
- In individuals with mild to moderate renal impairment, it should be used with caution, and frequent monitoring is advised.
Signiicant renal impairment:
- Those who have significant renal impairment shouldn't use it.

Dose in Liver disease:

There are no dosage adjustments provided in the manufacturer's labeling.

Side effects of Magnesium glucoheptonate (Magnelium):

Gastrointestinal:
- Diarrhea
- Nausea
- Vomiting
Other:
- Weakness
- lethargy
- hypotension
- cardiac arrhythmias

Contraindications to Magnesium glucoheptonate (Magnelium):

Patients with severe renal impairment should be avoided

Warnings and precautions

Neuromuscular disease
- Patients with myasthenia Gravis or neuromuscular disorders should be cautious about taking the drug.
Renal impairment
- Magnesium toxicity can occur in patients with renal impairment. It is best to avoid patients with severe renal impairment.

Magnesium glucoheptonate (United States: Not available): Drug Interaction

Risk Factor C (Monitor therapy)
Neuromuscular-Blocking Agents	The neuromuscular-blocking effect of neuromuscular-blocking agents may be strengthened by magnesium salts.
Calcium Channel Blockers	Magnesium salts' harmful or hazardous effects could be amplified. Calcium Channel Blockers' hypotensive effects may be strengthened by magnesium salts.
Risk Factor D (Consider therapy modification)
Alpha-Lipoic Acid	This may be less Properly absorbed when taken with magnesium salts. Magnesium salts may be less readily absorbed when alpha-lipoic acid is present.
Bictegravir	Products containing polyvalent cations may lower bictegravir's serum levels. Treatment: Bicategravir should be administered while fasting a minimum of 2hrs prior to or 6hrs after using products containing polyvalent cations. It is not advised to take bictegravir at the same time as or two hours after most polyvalent cation products.
Alfacalcidol	May raise the level of magnesium salts in the serum.
Bisphosphonate Derivatives	Products containing polyvalent cations may lower the level of bisphosphonate derivatives in the serum. The following oral drugs should not be used within the following time frames: 2hrs prior to or after tiludronate/clodronate/etidronate; 60 mins after oral ibandronate; or 30 mins after alendronate/risedronate. Pamidronate and zoledronic acid are exceptions.
Deferiprone	Products containing polyvalent cations may lower the level of deferiprone in the serum. Treatment: Give deferiprone at least four hours apart from oral drugs or dietary supplements containing polyvalent cations.
Calcitriol (Systemic)	May increase the serum's amount of magnesium salts. Treatment: If a patient is also taking calcitriol, you might want to use a phosphate-binding drug or an antacid that doesn't contain magnesium. If magnesium-containing products must be taken in conjunction with calcitriol, serum magnesium concentrations should be closely monitored.
Dolutegravir	Magnesium salts may reduce its serum concentration. Dolutegravir should be administered at least 2hrs prior to or 6hrs following the consumption of oral magnesium salts. Give the dolutegravir/rilpivirine combo product at least 4hrs prior to or 6hrs after taking oral magnesium salts.
Eltrombopag	Its serum levels may be decreased by products containing polyvalent cations. Eltrombopag should be administered at least 2hrs prior to or 4hrs following the administration of any oral drug containing polyvalent cations.
Doxercalciferol	Magnesium salts' hypermagnesemic impact might be enhanced. When treating individuals who are also on doxercalciferol, take into account utilising an antacid or phosphate-binding medicine that doesn't contain magnesium. Serum magnesium concentrations should be carefully watched if magnesium-containing products must be taken with doxercalciferol.
Gabapentin	Gabapentin's CNS depressive effects may be strengthened by magnesium salts. Magnesium sulphate at large doses administered intravenously or epidurally, in particular, may intensify gabapentin's depressive effects on the CNS. Magnesium salts may lower the level of gabapentin in the blood. Treatment: Give gabapentin at least two hours after taking an antacid that contains magnesium. Keep a watchful eye on the patients for signs of diminished response to gabapentin medication. If a high dosage of IV/epidural magnesium sulphate is given, keep an eye out for CNS depression.
Levothyroxine	Magnesium salts may reduce the blood's amount of levothyroxine. Treatment: Give oral magnesium salts and oral levothyroxine at least 4 hours apart.
Multivitamins/Fluoride (with ADE)	Fluoride and multivitamin (with ADE) serum levels may be decreased by magnesium salts. Magnesium salts in particular may lessen the absorption of fluoride. Treatment: Give magnesium salts at least 1 hour apart from taking a fluoride-containing product to prevent this potential interaction.
Mycophenolate	Magnesium salts may lower the level of mycophenolate in the serum. Treatment: Different doses of mycophenolate and magnesium salts taken orally. If mycophenolate and oral magnesium salts are taken at the same time, watch out for any diminished effects.
PenicillAMINE	Products containing polyvalent cations may lower the level of penicillAMINE in the serum. Treatment: Give oral medications containing polyvalent cations and penicillamine at least an hour apart.
Phosphate Supplements	The serum content of supplements containing phosphate may be lowered by magnesium salts. Management: Give oral phosphate supplements as widely apart as you can from giving an oral magnesium salt to lessen the significance of this interaction. Sodium Glycerophosphate Pentahydrate is an exception.
Quinolones	Quinolone serum levels may be lowered by magnesium salts. Treatment: Give oral quinolones before or after oral magnesium salts, depending on the drug (6 hrs for cipro/dela, 8 hrs for moxi, 3 hrs for gemi, 4 hrs for lome/pe, and 2 hrs for levo, nor, or ofloxacin or nalidixic acid). Other than LevoFLOXacin (Oral Inhalation).
Tetracyclines	Tetracyclines may be less readily absorbed when magnesium salts are present. applies only to oral forms of each drug. Eravacycline is an exception.
Trientine	Products containing polyvalent cations may lower the level of trientine in the serum. Management: Steer clear of combining the use of oral medications containing polyvalent cations with trientine. If you need to take oral iron supplements, space out the administration by two hours. Separate administration of other oral polyvalent cations by one hour if necessary.
Risk Factor X (Avoid combination)
Baloxavir Marboxil	Products containing polyvalent cations may lower the level of baloxavir marboxil in the serum.
Raltegravir	Avoid using magnesium salts orally or intravenously while taking raltegravir. There is currently no dosage separation schedule in place that sufficiently lowers the amount of interaction. Magnesium salts may lower the level of raltegravir in the blood.

Monitoring Parameters:

If the medicine is used for a long time or if the patient is at risk of developing magnesium toxicity, such as those with kidney failure, monitor the patient for cardiac arrhythmias.

How to administer Magnesium glucoheptonate?

It may be administered orally with meals.

Mechanism of action of Magnesium glucoheptonate (Magnelium):

Magnesium behaves as a cofactor for several enzymes in the body.
Magnesium is required for proper functioning of around 300 enzymes.
It is a cofactor of enzymes involved in carbohydrate, protein, and lipid synthesis.
It reduces serum cholesterol and acts on lipoprotein lipases.
It can also act on the sodium/potassium ATPase, resulting in the polarization and reorganization of neurons.

Excretion: